Intra-Cellular Therapies 과거 수익 실적

과거 기준 확인 0/6

Intra-Cellular Therapies은 연평균 5.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 12.9%의 비율로 수입이 증가했습니다. 매출은 연평균 63.9%의 비율로 증가했습니다.

주요 정보

5.8%

수익 성장률

15.8%

EPS 성장률

Pharmaceuticals 산업 성장	7.3%
매출 성장률	63.9%
자기자본 수익률	-7.5%
순이익	-14.1%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Intra-Cellular Therapies 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:23I 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Sep 24	614	-86	471
30 Jun 24	565	-84	445
31 Mar 24	514	-111	424
31 Dec 23	464	-140	410
30 Sep 23	420	-155	400
30 Jun 23	366	-184	383
31 Mar 23	311	-228	382
31 Dec 22	250	-256	359
30 Sep 22	188	-298	344
30 Jun 22	138	-321	326
31 Mar 22	103	-304	295
31 Dec 21	84	-284	273
30 Sep 21	71	-259	251
30 Jun 21	56	-237	233
31 Mar 21	38	-232	205
31 Dec 20	23	-227	186
30 Sep 20	10	-207	151
30 Jun 20	3	-187	113
31 Mar 20	1	-160	87
31 Dec 19	0	-148	65
30 Sep 19	0	-148	51
30 Jun 19	0	-155	44
31 Mar 19	0	-154	35
31 Dec 18	0	-155	30
30 Sep 18	0	-145	27
30 Jun 18	0	-126	24
31 Mar 18	0	-106	24
31 Dec 17	0	-98	24
30 Sep 17	0	-95	25
30 Jun 17	0	-102	26
31 Mar 17	0	-116	26
31 Dec 16	0	-116	25
30 Sep 16	0	-118	24
30 Jun 16	0	-120	22
31 Mar 16	0	-110	19
31 Dec 15	0	-105	18
30 Sep 15	0	-91	15
30 Jun 15	0	-65	14
31 Mar 15	0	-48	12
31 Dec 14	1	-31	10
30 Sep 14	1	-24	9
30 Jun 14	2	-22	8
31 Mar 14	2	-26	7
31 Dec 13	3	-27	6

양질의 수익: 23I 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 23I 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 23I 은(는) 수익성이 없지만 지난 5년 동안 연간 5.8% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 23I 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 23I 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 28.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 23I 현재 수익성이 없기 때문에 마이너스 자본 수익률( -7.54% )을 갖습니다.

Intra-Cellular Therapies 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.46 loss in 1Q 2023)

Full year 2023 earnings released: US$1.46 loss per share (vs US$2.73 loss in FY 2022)

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.45 loss per share (vs US$0.92 loss in 2Q 2022)

Recent updates

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

Intra-Cellular Therapies, Inc. Raises Financial Guidance for the Full Year 2024

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023)

Intra-Cellular Therapies, Inc. Raises Sales Guidance for 2024

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 2000 Dynamic Index

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.46 loss in 1Q 2023)

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 14, 2024

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

New minor risk - Shareholder dilution

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer

Full year 2023 earnings released: US$1.46 loss per share (vs US$2.73 loss in FY 2022)

New minor risk - Shareholder dilution

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024

Forecast to breakeven in 2025

EVP & Chief Commercial Officer recently sold €801k worth of stock

Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2022)

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.45 loss per share (vs US$0.92 loss in 2Q 2022)

Forecast to breakeven in 2025

Intra-Cellular Therapies, Inc. Announces CAPLYTA Data Presentations At the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.78 loss in 1Q 2022)

Full year 2022 earnings released: US$2.73 loss per share (vs US$3.50 loss in FY 2021)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Director recently sold €240k worth of stock

Independent Director recently sold €523k worth of stock

Independent Director recently sold €523k worth of stock

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$0.94 loss in 3Q 2021)

Independent Director recently sold €573k worth of stock

Second quarter 2022 earnings released: US$0.92 loss per share (vs US$0.85 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.65 loss in 1Q 2021)

Intra-Cellular Therapies, Inc. Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 09, 2022

Independent Director recently sold €736k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2024

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$0.79 loss in 3Q 2020)

Intra-Cellular Therapies, Inc. Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

Second quarter 2021 earnings released: US$0.85 loss per share (vs US$0.96 loss in 2Q 2020)

Forecast to breakeven in 2023

High number of new directors

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 1Q 2020)

Intra-Cellular Therapies Announces FDA Acceptance of Caplyta (Lumateperone) SNDAs for the Treatment of Bipolar Depression

Revenue beats expectations

Intra-Cellular Therapies Announces Expansion of Pipeline with the Introduction of New Molecular Entity, ITI-1284

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression

New 90-day high: €32.85

New 90-day high: €29.02

Intra-Cellular Therapies, Inc. Announces the Publication of Results from the CAPLYTA Clinical Trial (ITI-007-303)

New 90-day high: €27.41

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

New 90-day high: €23.82

Senior VP of Finance recently sold €174k worth of stock

Revenue beats expectations

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $350.00001 million.

New 90-day low - €15.16

New 90-day low - €16.08

First half earnings released